NASDAQ:CLDX - Celldex Therapeutics Stock Price, Forecast & News

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics's stock reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.09. The biopharmaceutical company earned $0.55 million during the quarter, compared to analysts' expectations of $1.26 million. Celldex Therapeutics had a negative net margin of 1,119.84% and a negative return on equity of 43.03%. View Celldex Therapeutics' Earnings History.

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Celldex Therapeutics.

2 equities research analysts have issued 1 year target prices for Celldex Therapeutics' shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate Celldex Therapeutics' stock price to reach $19.00 in the next year. This suggests a possible upside of 705.1% from the stock's current price. View Analyst Price Targets for Celldex Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celldex Therapeutics.

News stories about CLDX stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celldex Therapeutics earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Celldex Therapeutics.

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Corbus Pharmaceuticals (CRBP), Intrexon (XON), Micron Technology (MU), Novavax (NVAX), Dynavax Technologies (DVAX) and Exelixis (EXEL).

Celldex Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.09%). Company insiders that own Celldex Therapeutics stock include James J Marino and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

CLDX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include James J Marino and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLDX stock can currently be purchased for approximately $2.36.

Celldex Therapeutics has a market capitalization of $38.07 million and generates $9.54 million in revenue each year. The biopharmaceutical company earns $-151,180,000.00 in net income (profit) each year or ($6.82) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.View Additional Information About Celldex Therapeutics.

The official website for Celldex Therapeutics is http://www.celldex.com/.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]